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Abstract 
Background:Anxiety disorders pose serious public health problems.The data 
available on anxiety disorders in the transgender population is limited by the small 
numbers, the lack of a matched controlled population and the selection of a non- 
homogenous group of transgender people.  
Aims:The aims of the study were(1)To determine anxiety symptomatology (based 
on the HADS) in a non-treated transgender population and to compare them to a 
general population sample matched by age and gender;(2)To investigate the 
predictive role of specific variables, including experienced gender, self-esteem, 
victimization, social support, interpersonal functioning and cross-sex hormone use 
regarding levels of anxiety symptomatology;(3)To investigate differences in anxiety 
symptomatology between transgender people on cross-sex hormone treatment and 
those who are not. 
Methods:A total of 913 individuals, who self-identified as transgender attending a 
transgender health service during a three-year period agreed participation. For the 
first aim of the study 592 transgender people not on treatment were matched by age 
and gender with 3816 people from the general population. For the second and third 
aim the whole transgender population was included. 
Measurements:Socio-demographic variables and measures of depression and 
anxiety(HADS), self-esteem(RSE), victimisation(ETS), social support(MSPSS), and 
interpersonal functioning(IIP-32). 
Results:Compared with the general population transgender people had a nearly 3-
fold increased risk of probable anxiety disorder(all p < .05). Low self-esteem and 
interpersonal functioning were found to be significant predictors of anxiety 
symptoms.  Trans women on treatment with cross-sex hormones were found to have 
lower levels of anxiety disorder symptomatology.  
Conclusions:Transgender people (particularly trans males) have higher levels of 
anxiety symptoms suggestive of possible anxiety disorders, when compared to the 
general population. The findings that self-esteem, interpersonal functioning and 
hormone treatment is associated with lower levels of anxiety symptoms indicate the 
need for clinical interventions targeting self-esteem and interpersonal difficulties as 
well as the importance of quick access to transgender health services.  
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Introduction 
 
Transgender people are a diverse population of individuals who do not present 
and/or identify as the gender they were assigned to at birth, either some or all of the 
time (Richards and Barker, 2013).  Transgender identities include women and men, 
who feminize or masculinize their bodies with cross-sex hormone treatment (CHT) 
and/or gender confirming surgery (GCS), and other gender-variant individuals, who 
may identify and/or present in a way which is outside the gender dichotomy of 
man/woman (Richards et al., 2016). 
 
Transgender people have been found to face a number of difficulties and 
interpersonal challenges (such as disclosing their gender identity) (Bockting and 
Coleman, 2016). They have been found to suffer from high levels of discrimination 
and victimization (Claes et al., 2015; Kattari et al., 2015; Leppel, 2016; Lombardi et 
al., 2001) as well as rejection from family and loved ones (Koken et al., 2009). 
Possibly as a consequence, many transgender people have low self-esteem (Erich 
et al., 2010) and high prevalence rates of mental health problems, particularly 
anxiety disorders and depression (Arcelus et al., 2016; Bockting et al., 2013; Claes 
et al., 2015; Davey et al., 2014, 2016; Dhejne et al., 2016; Heylens et al., 2014a).  
 
Research in the transgender population pre-treatment using cross sectional data, 
have shown high levels of anxiety symptomatology in this population (Bockting et al., 
2013; de Vries et al., 2011; Heylens et al., 2014a; Reisner et al., 2015, 2016). High 
levels of anxiety symptomatology are particularly prevalent in transgender people 
before treatment (Bergero-Miguel et al., 2016; Colizzi et al., 2013; de Vries et al., 
2011; Gómez-Gil et al., 2012; Heylens et al., 2014a).   
 
Research looking at anxiety symptoms and anxiety disorders in the transgender 
population have found an association with frequent experiences of discrimination in 
employment and housing, violence, physical and verbal abuse, societal harassment 
related to gender presentation, perceived need to keep one’s transgender identity a 
secret and lack of gender confirming treatment (Bockting et al., 2013; Clements-
Nolle et al., 2006; McNeil et al., 2012). Some of these findings support the minority 
stress theory (Bockting et al., 2013; Meyer, 1995; 2003). However, these studies are 
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limited by the small numbers of transgender people as well as heterogeneity of the 
group (for instance, people at different stages of transition).  
 
Several studies have looked at to the role of gender confirming medical treatment 
(cross-sex hormone treatment (CHT) and gender affirming surgery (GAS)) in anxiety 
symptoms among the transgender population (Bouman et al., 2016a; Colizzi et al., 
2013, 2014; Davis and Colton Meier, 2014; De Vries et al., 2014; Dhejne et al., 2016; 
Gomez-Gil et al., 2012; Heylens et al., 2014b; Meier et al., 2011). These studies 
showed that gender confirming medical treatment improves mental health, including 
anxiety symptomatology. However, the results are not consistent (e.g., Reisner et al., 
2015) and limited by a small sample size (e.g., De Vries et al., 2014; Heylens et al., 
2014b) or by the lack of matched controls (e.g., Colizzi et al., 2013, 2014; Davis and 
Colton Meier, 2014; Gomez-Gil et al., 2012).  
 
This study addresses the aforementioned limitations of a small sample size, a lack of 
homogeneity and a matched control group.  The current study investigates the 
prevalence of possible or probable anxiety disorder in a large cohort of adult 
transgender people, who seek treatment at a national transgender health service; 
and the study compares this large cohort of adult transgender people to general 
population data matched by age and gender (experienced gender). 
 
This study has several aims. Firstly, to determine the levels of anxiety 
symptomatology suggesting possible and probable anxiety disorder in non-treated 
transgender people and to compare them with a cisgender (cis) population matched 
by age and gender. Secondly, to investigate the predictive role for anxiety disorders 
(possible and probable) of specific variables known to be associated with anxiety 
symptoms in the cisgender and transgender population such as age, gender, self-
esteem, social support, interpersonal functioning and victimisation and the use of 
CHT in transgender people (Bouman et al., 2016a; Claes et al., 2015; Colizzi et al., 
2014; Davey et al., 2014, 2015; Gomez-Gil et al., 2012; Kessler et al., 2005a; 
Kessler et al., 2005b; McLean et al., 2011; Meier et al., 2011). Finally, to investigate 
differences in anxiety scores between transgender people on cross-sex hormone 
treatment (CHT) with those not on cross-sex hormone treatment (non-CHT). For the 
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last two aims the whole population of transgender people (on CHT and not on CHT) 
will be selected.  
 
Based on the literature regarding anxiety and transgender people, it was 
hypothesized that levels of anxiety will be higher in the transgender population 
compared to the general population, and associated with psychopathology, 
decreased self-esteem and social support, discrimination, lower levels of 
interpersonal functioning and lack of CHT treatment.  There is no clear hypothesis 
regarding the relationship between gender and anxiety symptoms. Studies in the 
general population suggest that cisgender women present with higher levels of 
anxiety symptoms than cisgender men, which may suggest that trans women 
present with higher anxiety symptoms too.  There is, however, also the possibility 
that genetic factors play a role in the aetiology of anxiety disorders, and 
consequently a predisposition to develop anxiety disorders may relate to one’s 
assigned gender at birth.  
 
Methods 
Participants and Procedures 
Transgender participants 
The sample consisted of all individuals who self-identify as transgender and attended 
for an assessment to a national transgender health service in X during a 3-year 
period, between November 2012 and October 2015. For the first aim of the study 
only individuals not on treatment with cross-sex hormones (non-CHT) before 
assessment will be selected in order to have a homogeneous group.  
Following assessment, the transgender person is considered for entry into the 
treatment programme.  Treatment, including CHT and GAS is free at the point of 
access in the National Health Service (NHS) in the United Kingdom for all citizens. 
Patients will usually start CHT, following informed consent, if there are no physical 
contraindications. Chest reconstructive surgery is generally available to trans men 
after being on testosterone treatment for a minimum of 6 months.  Genital 
reconstructive surgeries are generally available to transgender people after being in 
the treatment programme for a minimum of 12 months. We acknowledge that not all 
transgender people wish to take cross-sex hormones or undergo gender confirming 
surgeries; a growing number of transgender people express a wish for partial 
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treatment (Beek et al., 2015).  Once transgender people have undergone their 
desired treatment, follow-up care can be organised at the service, if they wish (Wylie 
et al., 2014).  
Prior to the clinical assessment every patient was invited to participate in the study, 
and if agreed to complete a battery of questionnaires. The study received ethical 
approval from the NHS Ethics committee and from the Research and Development 
Department from X in line with Health Research Authority guidance (HRA, 2013). 
 
Control group 
A total of 3816 adults from the general population with an age range of 16-92 who 
participated in another study (Crawford et al., 2009) was used as controls and 
matched by age and gender. These samples were recruited between 2006 and 
2009. In order to increase the normative data, a broad representation of the general 
adult UK population was selected, in terms of the age, education, and gender 
(although, in most cases, females were over sampled). The recruitment process 
included a variety of sources such as large and small businesses, public service 
organizations, community centres, and recreational groups. The majority of 
participants were recruited from urban/ suburban locations, although rural/semi-rural 
people were also represented. As per the transgender group, participants were 
invited to complete the Hospital Anxiety and D pression Scale (Zigmond & Snaith, 
1983) and place them in a sealed envelope. The questionnaires were filled out 
anonymously. The combined refusal/non-return rates ranged from approximately 
17% to 21%.  
 
Ethical approval was obtained from the Psychology Ethics Committee of the 
University of X. 
 
Main Outcome Measures 
 
The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) is 
a 14-item self-report screening scale that was originally developed to indicate the 
possible presence of anxiety and depression states in the setting of a medical non-
psychiatric outpatient clinic.  HADS consists of two subscales, HAD-Anxiety (HAD-A) 
and HAD-Depression (HAD-D). For this study only the subscale of anxiety will be 
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used. This subscale has seven items, rated on a 4-point Likert scale (ranging from, 
as much as I always do (0); not quite so much (1); definitely not so much (2); to not 
at all (3)), indicating symptoms of anxiety during the preceding week.  A score of 0-7 
on either scale is regarding as being in the normal range (no symptoms), a score of 
8-10 is suggestive of the presence of an anxiety disorder (possible symptoms), and a 
score of 11 or higher indicates the probable presence of an anxiety disorder 
(symptoms) of the respective state.  Maximum subscales scores are 21 for anxiety. 
The HADS was found to perform well in assessing the symptom severity and 
caseness of anxiety disorders in both somatic, psychiatric and primary care patients 
and in the general population (Bjelland et al., 2002) and it has been previously used 
with transgender individuals (Bouman et al., 2016a; Gomez-Gil et al., 2012). A 
number of researchers have explored HADS data to establish the cut-off points for 
caseness of anxiety. Bjelland et al. (2002) through a systematic review of a large 
number of studies identified a cut-off point of 8/21 for anxiety. For anxiety (HADS-A) 
this gave a specificity of 0.78 and a sensitivity of 0.9. In this study, the Cronbach’s 
alpha was 0.68 for the anxiety scale. 
 
The Rosenberg Self-Esteem Scale (RSE) (Rosenberg, 1965) is a self-report 
measure of global self-esteem. Items are rated on a 4-point rating scale ranging from 
0 (‘Strongly disagree’) to 3 (‘Strongly agree’). Its total score is calculated by summing 
the item scores with higher scores indicating higher self-esteem.  The RSE has been 
empirically validated and administered previously to transgender individuals (Arcelus 
et al., 2016; Vocks et al., 2009). In this study the Cronbach’s alpha was 0.91. 
 
The Experiences of Transgender Phobia Scale (Lombardi et al., 2001) assesses 
experiences of discrimination or victimization on the basis of gender identity or 
gender presentation. The questionnaire was based on the Transgender Violence 
Study and measured people’s lifetime experiences of violence and harassment and 
experiences of any form of economic discrimination as a result of being transgender 
(e.g., verbal abuse, physical abuse, fired from a job, problems getting a job, and 
problems getting health or medical services due to gender identity or presentation). 
All five items are to be rated on a four-point Likert scale ranging from 0 (‘never‘) to 3 
(‘several times’). This scale has been previously used with transgender individuals 
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(Arcelus et al., 2016; Bouman et al., 2016a,b; Claes et al., 2015). In this study the 
Cronbach’s alpha was 0.59. 
 
The Multidimensional Scale of Perceived Social Support (MSPSS) (Zimet et al., 
1990) is a 12-item, self-report scale designed to tap social support from family, 
friends, and significant others. Items are rated on a 7-point Likert scale ranging from 
1 (‘very strongly agree’) to 7 (‘very strongly disagree’). The instrument includes three 
subscales to address these three types of support (family, friends, significant others). 
The mean total and subscale scores range from 1 to 7, and a higher score indicates 
greater perceived social support. This scale has recently been used in transgender 
populations (Boza et al., 2014; Davey et al., 2014, 2016). In this study the 
Cronbach’s alpha was 0.89 for the total scale. 
 
The Inventory of Interpersonal Problems (IIP-32) (Barkham et al., 1996) 
measures interpersonal difficulties. It consists of 32 items to be rated on a 5-point 
Likert scale ranging from 0 (‘Not at all’) to 4 (‘Extremely’). There are eight subscales 
of interpersonal problems: Hard to be Assertive, Hard to be Sociable, Hard to be 
Supportive, Hard to be Involved, Too Dependent, Too Caring, Too Aggressive, and 
Too Open. A total mean score provides a global measure of interpersonal distress. 
Higher subscale scores indicate greater interp rsonal difficulties. The IIP-32 is a 
shortened version of the original IIP, yet the psychometric properties are retained; a 
confirmatory factor analysis demonstrated high reliability with alpha coefficients of 
0.70 to 0.88 (Barkham et al., 1996). The IIP-32 has been used successfully in both 
non-clinical (Berry et al., 2006) and clinical samples (Bouman et al., 2016b; Davey et 
al., 2015). In this study the Cronbach’s alpha was 0.87 for the total scale. 
  
Data Analysis 
All quantitative data analyses were performed by means of SPSS 22 (IBM, 2013). 
First descriptive statistics were applied. For the first aim, only transgender people will 
be included in order to have a homogenous group. As per the authors advice based 
on the HADS three categories will be developed: 1) people with no anxiety disorder, 
2) people with symptoms suggesting of a possible anxiety disorder and, 3) people 
with symptoms suggesting a probable anxiety disorder. We used the Chi-Square 
Test Statistic to calculate the association between the three levels of anxiety 
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symptomatology and the participant status (transgender and controls) for the total 
group and for males/females separately. For the second aim, the prediction of the 
presence/absence of an anxiety disorder based on self-esteem, social support, 
interpersonal functioning and victimization and the use of CHT in transgender people 
controlled for gender and age, we performed a hierarchical regression analysis, with 
the presence/absence of the anxiety disorder as a dependent variable (dummy), age 
and gender (step 1) as control variables and the other variables (step 2) as 
predictors. For the third aim, the association between the presence/absence of an 
anxiety disorder and the use/not use of CHT, we calculated the Chi Square Test 
Statistic for the total group, and males/females separately. The level of significance 
used was p < 0.05.  
 
Results 
Socio-demographic characteristics of the whole sample regarding 
During the recruitment period of 3 years 913 individuals who fulfilled the inclusion 
criteria agreed to participate. Twenty-five individuals (2.6%) did not agree 
participation, which gives a response rate of 97.4%. The age range of the 
participants was 15-79 years with a mean age of 30.4 years (SD= 13.9); 582 (63.7%) 
patients identified themselves as trans females (assigned male at birth) and 331 
(36.3%) as trans males (assigned female at birth). Of the total sample of 913 
transgender people 640 (70,1%) were not on cross-sex hormone treatment, 259 
(28.4%) were on CHT, whilst for 14 patients (1.5%) this information was not available 
and they were removed for further analyses.  
 
Comparative analyses between transgender people not on CHT and controls.  
For the first aim of the study only people not on CHT were selected (n=640). Of the 
640 patients in the non-CHT group the age range was 16-79 years with a mean age 
of 28.6 years (SD= 12.8); 393 (61.4%) patients identified as trans females (assigned 
male at birth) and 247 (38.6%) were trans males (assigned female at birth). This 
group was matched by age and experienced gender with the control group. Of the 
640 patients in the non-CHT group 48 (7.5%) could not be matched due to 
insufficient numbers for that age in the control data.  This group consisted of 19 trans 
females and 28 trans males aged 17 and 18 with an average age of 17.3 years (SD= 
0.48). The remaining sample of 592 non-CHT patients were block matched with the 
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control population data base. This meant that for the first aim, a total of 1184 
participants were selected, 592 in each group. 
 
Out of the 592 transgender and cisgender participants, 218 (36.8%) were trans and 
cis females and 374 (63.2%) were trans and cis males respectively. As Table 1 
shows the control group were significantly more prevalent in the category of ‘No 
Anxiety Disorder’ compared to the transgender group, whereas the transgender 
people were significantly more prevalent in the categories ‘Possible and Probable 
Anxiety Disorder’ compared to the control group. This difference was statistically 
significant [Χ2(2) = 148.997, p < .001]. When comparing trans with cis men [Χ
2
(2) = 
128,521, p < .001] and trans with cis women [Χ2(2) = 21,443, p < .001], the difference 
was still statistically significant.  
 
(Insert Table 1. about here) 
 
Predictors of anxiety disorders (probable and possible) among the whole 
transgender population 
 
In order to analyze the predictors of anxiety in the transgender population, the whole 
group of 913 transgender people (excluding the 14 people without information 
regarding CHT), were included (giving a total of 899 individuals). Those in the 
category of probable and possible anxiety symptoms were grouped together into one 
category (anxiety disorder).  A linear hierarchical regression analysis with the 
presence or absence of anxiety disorder as dependent variable, age and gender as 
control variables, and self-esteem, social support, interpersonal functioning and 
victimization and presence and absence of CHT as independent variables was 
performed. The results showed that low self-esteem and interpersonal problems 
were the only significant predictors for a transgender person attending transgender 
health services to suffer from a possible and probable anxiety disorder.  
Interpersonal functioning was a stronger predictor (See Table 2). 
 
 
(Insert Table 2. about here) 
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Comparison between people on CHT and those not on CHT 
 
Analyses comparing transgender people on CHT with those not on CHT found a 
statistically significant difference between both groups with more transgender people 
using CHT in the category of no anxiety disorder compared to those on not on CHT 
[Χ2(1) = 20,266, p < .001]. The latter group is more prevalent in the category anxiety 
disorder (see Table 3.). As the use of CHT was more prevalent among trans females 
and anxiety symptoms were more prevalent among trans men the same analyses 
were performed according to gender. The new analyses showed that for trans 
females being on CHT was associated with less anxiety disorder as there were more 
trans females not on CHT in the category of anxiety disorders when compared to 
trans females on CHT [Χ2(1) = 21,802, p < .001]. This was not the case for trans 
males [Χ2(1) = 1,379, p < .240]. 
 
 
(Insert Table 3 about here) 
 
 
 
Discussion 
Anxiety disorders are the most common mental disorders, with a reported 12-month 
prevalence of 18.1% and a lifetime prevalence of 28.8% (Kessler et al., 2005a; 
Kessler et al., 2005b).  Moreover, women are significantly more likely than men to 
develop an anxiety disorder throughout the lifespan (McLean et al., 2011). Owing to 
their high prevalence, combined with an often early onset and chronic course, 
anxiety disorders are the second most important cause of disability worldwide within 
the group of mental and behavioural disorders (Whiteford et al., 2013; de Vries et al., 
2016). This study found high rates of possible (32.8%) and probable (36.0%) current 
anxiety disorder in untreated transgender people attending a transgender health 
service.  Compared with a cisgender matched control group from the general 
population, transgender people had an almost 3-fold increased risk of probable 
anxiety disorder.  Trans males showed higher rates of possible and probable anxiety 
disorder (71.1%) than trans females (59.8%), which would be in keeping with the 
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literature on gender differences in anxiety disorders, if the pattern of birth gender is 
followed (McLean et al., 2011). Studies looking as to why anxiety symptoms are 
more prevalent among individuals whose gender is assigned female at birth, suggest 
that differences in neurobiological make-up may account for these differences. The 
brain system involved in the fight-or-flight response is activated more readily in 
female-assigned-at-birth individuals and stays activated longer than male-assigned-
at-birth individuals, partly as a result of the action of estrogen and progesterone. The 
neurotransmitter serotonin may also play a role in responsiveness to stress and 
anxiety. Some evidence suggests that the brain of individuals, whose sex is 
assigned female at birth does not process serotonin as quickly as their male 
counterparts. Recent research has also found that female-assigned-at-birth 
individuals are more sensitive to low levels of corticotropin-releasing factor (CRF), a 
hormone that organizes stress responses in mammals, making them twice as 
vulnerable as their male-assigned-at-birth counterparts to stress-related disorders 
(Bangasser et al., 2016). 
This study found low self-esteem and interpersonal functioning to be predictors of 
anxiety disorder, which highlights the importance of psychological intervention and 
support in this vulnerable group. Psychological treatment aiming at improving self-
esteem and interpersonal functioning may help transgender individuals at risk of 
developing anxiety disorder when going through the transitional process.  Various 
psychological treatments have proven efficacious in increasing self-esteem (Morton 
et al., 2012; Fennel, 2006; Rigby and Waite, 2007). Similarly, interpersonal 
psychotherapy (IPT) has been found efficacious in reducing interpersonal problems. 
As IPT has been successfully used in various populations (e.g., Arcelus et al., 2011; 
Hara et al., 2000; Mufson et al., 2013), it could be adapted for use within the 
transgender population (Budge, 2013). For those transgender patients who meet a 
diagnosis of anxiety disorder current treatment approaches apply, including 
consideration of pharmacotherapy and/or psychological treatment (Baldwin et al., 
2014; Iacoviello & Charney, 2015).  
Further findings confirmed the benefits of cross-sex hormone treatment, particularly 
for trans women on CHT, as they were significantly more prevalent in the category 
no anxiety disorder compared to those who do not use cross-sex hormones.  That 
these findings do not apply to trans men is surprising, and certainly do not reflect our 
clinical experience.  One explanation may be that the higher risk of developing 
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anxiety disorder for people whose sex is female assigned at birth offsets the positive 
psychological benefits of CHT in trans men.  This specific area needs further study.  
The findings confirm existing research (Gomez-Gil et al., 2012; Colizzi et al., 2014; 
De Vries et al., 2014; Heylens et al., 2014b; Bouman et al., 2016) and add further 
weight to the rationale of early treatment for gender dysphoria. In many countries, 
long waiting lists and lack of clinical services for transgender people combined with 
overly prescriptive pathways to access CHT in Standards of Care (Coleman et al., 
2012; Wylie et al., 2014) continue to be significant barriers to treatment for 
transgender people.  Moreover, these barriers to access treatment are likely to 
further increase the rate of anxiety disorders; also, they tend to lead to self-
prescribing via the Internet without medical supervision (Mepham et al., 2014). 
 
There are aspects of the study that warrant attention in relation to limitation of the 
results. First, the study is limited by selecting a specific population of treatment 
seeking individuals and doing so in a country in which the waiting list for a first 
appointment at a transgender health service is long. Hence, the results may not be 
generalizable to other transgender people who do not access clinical services or to 
other countries with different healthcare systems. Second, the research makes use 
of self-reported questionnaires, and although most are adequately validated and 
have been used in transgender populations, future research could use structured 
clinical interviews to differentiate the clinical group from those with and without 
anxiety disorder and other psychiatric morbidity. Furthermore, a limitation of the 
study is the cross-sectional nature of the data. From the current data, it is not 
possible to determine whether the psychological benefits associated with the use of 
CHT predate or are a consequence of disclosure of experienced gender and/or 
social gender role transition. It also may be that those with better self-esteem and 
less psychopathology feel more confident to commence treatment without medical 
advice. They may use the support and advice of their friends who also may be taking 
CHT. The lack of information regarding the gender identity of the control group used, 
makes it impossible to generalize the results to the transgender population, as some 
of people in control group may also identify as transgender. This information was not 
asked, although, given the low prevalence the impact on the final results is likely to 
be negligible (Arcelus et al., 2015). Many studies in the field of transgender health 
have included people fulfilling a diagnosis as per the ICD or DSM (e.g., Colizzi et al., 
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2013; de Vries et al., 2011; Gómez-Gil et al., 2012; Heylens et al., 2014ª) as well as 
relying on self-identification regarding one’s gender (e.g., Bockting et al., 2013; Davis 
& Colton Meier, 2014; Reisner et al., 2016; Warren et al., 2016). This study has not 
used a diagnosis to classify people, but selected a population of people who self-
identify as transgender and access transgender health services for treatment. It can 
be argued that the population selected in this study may be slightly different to the 
one fulfilling diagnostic criteria, although this is not our clinical impression, but we do 
want to acknowledge this difference.  A final note on the generalizability of the 
findings is that there are particularities with regards to medical treatment and 
legislation for transgender person people in the UK. For example, some aspects of 
gender reassignment treatment (e.g. CHT and/or GCS) are available through the 
NHS free at the point of access, and the Gender Recognition Act 2004 provides legal 
recognition of a trans individual’s experienced gender. In addition, the Sex 
Discrimination (Gender Reassignment) Regulations Act 1999, and its amendment in 
2008, deemed it unlawful to discriminate on the basis of gender reassignment within 
employment and vocational training, as well as within the provision of goods, 
facilities, and services. Consequently, the experience of living as a transgender 
person in the United Kingdom may be different from living as a transgender person 
in other countries (Davey et al., 2015).  
In spite of the above limitations the strength of the paper is the large group of 
transgender and control group involved, making this one of the largest studies in this 
field. The study is also strengthened by the matching of groups (transgender and 
controls and transgender on CHT and not on CHT). The lack of matching between 
groups in the transgender literature has been criticized previously (Dhejne et al., 
2016). 
 
Notwithstanding the aforementioned limitations, this study clearly shows that 
treatment-seeking transgender individuals have a high prevalence rate of possible 
and probable anxiety disorder compared to the general population.  Having an 
experienced male gender, low self esteem, interpersonal problems and lack of cross-
sex hormone treatment are specifically associated with an increased likelihood of co-
existing anxiety disorder in transgender people, having low self esteem and 
interpersonal problems being the main predictors for anxiety. Mental health services 
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should take heed of these findings to improve outcomes in this vulnerable group of 
individuals.  
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Table 1: Comparison between the number of transgender (TG) people (men, women and total) and cisgender controls regarding the existence or 
not of anxiety disorders (n=1184) 
 
 
 Both Genders 
(n=1184) 
Trans males 
(n=436) 
Trans females  
(n=748) 
 TG 
(n=592) 
Controls 
(n=592) 
TG 
(n=218) 
Controls 
(n=218) 
TG 
(n=374) 
Controls 
(n=374) 
No Anxiety disorder n(%) 185 (31.2)* 388 (65.5)* 72 (33.0)* 120 (55.0)* 113 (30.2)* 268 (71.6)* 
 
Anxiety disorders 
n(%) 
Possible n(%)  
407 
(68.8)* 
194 
(32.8) 
 
204 
(34.5)* 
126 
(21.3) 
 
146 
(67.0)* 
67 
(30.7) 
 
98 
(45.0)* 
58 
(26.6) 
 
261 
(69.8)* 
126 
(33.7) 
 
106 
(28.4)* 
68 
(18.2) 
Probable n(%) 213 
(36.0) 
78 
(13.2) 
78 
(36.3) 
40 
(18.4) 
133 
(36.1) 
38 
(10.2) 
*p<.05 
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Table 2. Predictive role of age, gender, self-esteem, social support, interpersonal function and victimization in transgender people with possible 
and probable anxiety disorder (as one category) compared to transgender people with no anxiety disorder. 
 
Model 
Unstandardized Coefficients Standardized Coefficients 
t p B Std. Error Beta 
1 (Constant) ,824 ,076  10,780 ,000 
Age -,005 ,001 -,143 -3,830 ,000 
Assigned Gender -,028 ,037 -,028 -,751 ,453 
2 (Constant) ,634 ,107  5,911 ,000 
Age ,001 ,001 ,028 ,812 ,417 
Assigned Gender ,008 ,031 ,008 ,239 ,811 
CHT pre assessment -,001 ,013 -,001 -,043 ,966 
Global score MSPSS -,002 ,001 -,056 -1,754 ,080 
Total RSE -,019 ,003 -,259 -6,404 ,000 
Global IIP score ,256 ,028 ,348 9,243 ,000 
Total Transphobia ,006 ,006 ,030 1,002 ,317 
a. Dependent Variable: HADS score; * p < 0.05 
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Table 3. Differences in anxiety symptomatology based on the HADS in transgender people on cross-sex hormone treatment (CHT) and those who 
are not on treatment (n= 899) 
 
 
 
 
*p < 0.05 
 
 
 
 
 
 Transgender people not on CHT 
N(%) 
Transgender people on CHT 
(N(%) 
 All 
(n=640) 
Trans female 
(n=393) 
Trans male 
(n=247) 
All  
(n=259) 
Trans female 
(n=179) 
Trans male 
(n=80) 
No Anxiety disorder (Score 0-7) 
 
202 (31.5)* 118 (30.0)* 84 (34.0) 123 (47.5) * 90 (50.3)* 33 (41.2) 
Possible or probable anxiety disorder (Score ≥ 8)  438 (68.5)* 275 (70.0)* 163 (66.0) 136 (52.5)* 89 (49.7)* 47 (58.8) 
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